Navigation Links
Robbins & Myers Reports Additional Gain and Increases Earnings Guidance
Date:4/2/2008

DAYTON, Ohio, April 2, 2008 /PRNewswire-FirstCall/ -- Robbins & Myers, Inc. (NYSE: RBN) today announced that certain contingency obligations relating to the sale of two of its Romaco product lines in fiscal year 2006 expired on March 31, 2008. As a result, the Company expects to recognize an additional pretax gain on that sale of approximately 3.5 million euros, or $5.4 million at current exchange rates, in its third fiscal quarter ending May 31, 2008.

This gain, which was not included in the Company's previously issued earnings guidance, is expected to increase diluted earnings per share (DEPS) for its third quarter and full year of fiscal 2008 by approximately $0.11 per share. Therefore, the Company increased its third quarter fiscal 2008 DEPS guidance from $0.42-$0.47 to $0.53 to $0.58 and its full year fiscal 2008 guidance from $1.82-$1.92 to $1.93-$2.03.

About Robbins & Myers

Robbins & Myers, Inc. is a leading supplier of engineered equipment and systems for critical applications in global energy, industrial, chemical and pharmaceutical markets.

In addition to historical information, this release contains forward- looking statements identified by use of words such as "expects," "anticipates," "believes," and similar expressions. These statements reflect management's current expectations and involve known and unknown risks, uncertainties, contingencies and other factors that could cause actual results, performance or achievements to differ materially from those stated. The most significant of these risks and uncertainties are described in our Form 10-K and Form 10-Q reports filed with the Securities and Exchange Commission and include, but are not limited to: a significant decline in capital expenditures in the specialty chemical and pharmaceutical industries; a major decline in oil and natural gas prices; foreign exchange rate fluctuations; work stoppages related to union negotiations; customer order cancellations; business disruptions caused by the implementation of business computer systems; our ability to comply with the financial covenants and other provisions of our financing arrangements; events or circumstances which result in an impairment of assets; the potential impact of U.S. and foreign legislation, government regulations, and other governmental action, including those relating to export and import of products and materials, and changes in the interpretation and application of such laws and regulations; the outcome of audit, compliance, administrative or investigatory reviews; and general economic conditions that can affect demand in the process industries. Except as otherwise required by law, we do not undertake any obligation to publicly update or revise these forward- looking statements to reflect events or circumstances after the date hereof.


'/>"/>
SOURCE Robbins & Myers, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Robbins & Myers to Release Fourth Quarter and 2007 Fiscal Year Results on Monday, October 15, 2007
2. Robbins & Myers Announces Regular Quarterly Cash Dividend
3. Robbins Bros. Gives Water at AIDS Walk L.A.
4. Robbins & Myers Presenting at Bear Stearns 3rd Annual Commodities and Capital Goods Conference November 28, 2007
5. Robbins & Myers to Present at Merrill Lynch Growth Industrials Conference December 13, 2007
6. Robbins & Myers to Present at Gabelli Conference
7. Robbins & Myers Schedules Second Quarter Fiscal 2008 Financial Results Conference Call
8. Bristol-Myers Squibb Announces Dividend
9. Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
10. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
11. Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... 26, 2017 , ... Amir Qureshi, MD is the first physician in Arkansas ... stimulation system. The Nuvectra™ Algovita SCS System has been FDA approved as a treatment ... in Arkansas to introduce the most powerful SCS system and the only stretchable lead ...
(Date:5/26/2017)... ... May 26, 2017 , ... On May 24, the ... narrowly passed the U.S. House on May 4, would result in 23 million Americans ... continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). , ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a ... announce a new, informational blog post on insurance options. If a Bay Area patient ... may help save time and money. Visiting an in-network provider for a second opinion ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Cactus Jack: Against ... on so many others. “Cactus Jack: Against All Odds” is the creation of ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter ...
(Date:5/24/2017)... Hills, CA (PRWEB) , ... May 24, 2017 , ... ... announced today its participation in nVerge 2017 – a one-day technology conference in San ... Altec’s document management solution, which allows users to fully utilize and enhance their Sage ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: